Safety and efficacy of domestic clopidogrel on patients with acute coronary syndrome after implantion of multiple coronary stents

张荣林,童廉琦,乔青,宋杰,王涟,张静梅,李虎,徐标

DOI: https://doi.org/10.3969/j.issn.1673-9523.2009.24.009

2009-01-01

Abstract:Objective To observe the therapeutic effect of domestic clopidogrel on patients with acute coronary syndrome(ACS)after multi-stents-planted percutaneous coronary intervention.Methods From Octo-ber 2006 to March 2008,166 patients with ACS admitted in the department of cardiology of Nanjing Drum Tower Hospital were included,and more than two stents were implanted in each patient.All patients were treated with routine pharmacotherapeutics regimen,and they were divided into two groups:domestic clopidogrel(TAL-COM)group and imported clopidogrel(PLAVIX)group,while each patient took a loading dose of 300 mg be-fore PCI and a maintenance dose of 75 mg domestic or imported clopidogrel after PCI respectively.The inci-dence of major clinical cardiovascular events(MACE)and hemorrhagic events were followed up during 6 months after PCI procedure.Results There were no statistic differences in baseline and PCI characteristic be-tween two groups(P > 0.05).During six-month follow-up,there were no differences in the occurrence rate of major clinical cardiovascular events and hemorrhagic events between two groups(P > 0.05).Conclusions As adjunctive treatment of multi-stents-planted PCI in patients with ACS,TALCOM and PLAVIX has the similar efficiency of antiplatelet.Comparing with the PLAVIX,the efficacy and safety of TALCOM has been confirmed in this study.